Replies to post #253247 on Biotech Values

[Whalatane]

Yes thx for pointing that out . They also have the Kidney Act now in the Senate IIRC

$ARDX -FROM CANTOR CONFERENCE
HR 5074 and S 4510
We have 24 Sponsors / Co-Sponsors and this is truly Bi-Partisan with strong support

It has already passed the House Ways & Means Cmte and the Energy and Commerce Cmte so waiting for a floor vote.

We have many avenues for this to be settled and are hopeful to hear something by the end of the year before patients lose access to this drug
This can happen by Stand Alone HC Bill, Omnibus Bill / Mini or in the CR inclusion

Kiwi

[DewDiligence]

Another “Chevron” case—>GLP-1 compounders sue FDA:

https://www.fiercepharma.com/pharma/compounders-sue-fda-removing-eli-lillys-tirzepatide-shortage-list

…last week, when the FDA removed Lilly’s tirzepatide [Zepbound] from its drug shortage list, it erased the compounders’ qualification to manufacture one of their two new cash cows [the other one being semaglutide (Wegovy)].

In response, a compounding industry group has sued the FDA, claiming its action to remove Lilly’s Mounjaro and Zepbound from the shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.”